University of California, Irvine Researchers Demonstrate Drug Candidate ShK-186, Derived From Sea Anemone Venom, Effective in Anti-Obesity Studies
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
IRVINE, Calif. & SEATTLE--(BUSINESS WIRE)--Scientists at UC Irvine reported this week that a synthetic compound ShK-186, originally derived from a sea anemone toxin, has been found to enhance metabolic activity and shows potential as a treatment for obesity and insulin resistance. The findings, published the week of May 27 in the Proceedings of the National Academy of Sciences, reveal that ShK-186 selectively blocks the activity of a protein that promotes inflammation through the Kv1.3 potassium channel. The study presents the first evidence that the drug candidate – which in March showed positive results in a Phase 1 safety clinical trial – may also work in an anti-obesity capacity.
Help employers find you! Check out all the jobs and post your resume.
IRVINE, Calif. & SEATTLE--(BUSINESS WIRE)--Scientists at UC Irvine reported this week that a synthetic compound ShK-186, originally derived from a sea anemone toxin, has been found to enhance metabolic activity and shows potential as a treatment for obesity and insulin resistance. The findings, published the week of May 27 in the Proceedings of the National Academy of Sciences, reveal that ShK-186 selectively blocks the activity of a protein that promotes inflammation through the Kv1.3 potassium channel. The study presents the first evidence that the drug candidate – which in March showed positive results in a Phase 1 safety clinical trial – may also work in an anti-obesity capacity.
Help employers find you! Check out all the jobs and post your resume.